keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/29788385/systematic-review-and-meta-analysis-vedolizumab-and-postoperative-complications-in-inflammatory-bowel-disease
#1
Diana E Yung, Nir Horesh, Amy L Lightner, Shomron Ben-Horin, Rami Eliakim, Anastasios Koulaouzidis, Uri Kopylov
Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy. Methods: A systematic review with a meta-analysis of the existing literature was conducted...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788318/effectiveness-and-safety-of-vedolizumab-in-anti-tnf-na%C3%A3-ve-patients-with-inflammatory-bowel-disease-a-multicenter-retrospective-european-study
#2
Uri Kopylov, Bram Verstockt, Luc Biedermann, Shaji Sebastian, Daniela Pugliese, Elena Sonnenberg, Peter Steinhagen, Naila Arebi, Yulia Ron, Torsten Kucharzik, Xavier Roblin, Bella Ungar, Ariella Bar-Gil Shitrit, Sandro Ardizzone, Pauliina Molander, Marina Coletta, Laurent Peyrin-Biroulet, Peter Bossuyt, Irit Avni-Biron, Emmanouela Tsoukali, Mariangela Allocca, Konstantinos Katsanos, Tim Raine, Taina Sipponen, Gionata Fiorino, Shomron Ben-Horin, Rami Eliakim, Alessandro Armuzzi, Britta Siegmund, Daniel C Baumgart, Nikolaos Kamperidis, Nitsan Maharshak, Christian Maaser, Gerassimos Mantzaris, Henit Yanai, Dimitrious K Christodoulou, Iris Dotan, Marc Ferrante
Background: Vedolizumab (VDZ) is effective for treatment of ulcerative colitis (UC) and Crohn's disease (CD). In GEMINI trials, anti-tumor necrosis factor (anti-TNF)-naïve patients had a superior response compared with anti-TNF-exposed patients. In real-world experience (RWE), the number of included anti-TNF-naïve patients was low. We aimed to evaluate the effectiveness and safety of VDZ in anti-TNF-naïve patients in an RWE setting. Methods: This retrospective multicenter European pooled cohort study included consecutive active anti-TNF-naïve IBD patients treated with VDZ...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788272/therapeutic-drug-monitoring-with-ustekinumab-and-vedolizumab-in-inflammatory-bowel-disease
#3
Sophie Restellini, Reena Khanna, Waqqas Afif
In patients with Crohn's disease (CD) and ulcerative colitis (UC), the use of therapeutic drug monitoring (TDM) with TNF-α antagonists has led to a personalized approach to optimize treatment and has been shown to be cost-effective. The utility of this TDM-based personalized approach for novel biologic agents, which target different inflammatory pathways, is unclear. Commercial assays for ustekinumab (UST) and vedolizumab (VDZ) are available, but there is little available guidance for clinicians regarding the use of TDM with these drugs...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788248/respiratory-tract-infections-in-patients-with-inflammatory-bowel-disease-safety-analyses-from-vedolizumab-clinical-trials
#4
Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake, Simon P L Travis
Background and Aims: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods: Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab in ulcerative colitis [UC; GEMINI 1] and Crohn's disease [CD; GEMINI 2], and a long-term safety study [UC and CD] were pooled...
May 17, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29788240/predictors-and-management-of-loss-of-response-to-vedolizumab-in-inflammatory-bowel-disease
#5
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, Prianka Chilukuri, Joseph Meserve, Khadija Chaudrey, Jenna L Koliani-Pace, Robert Hirten, David Faleck, Morris Barocas, Michelle Luo, Karen Lasch, Brigid S Boland, Siddharth Singh, Niels Vande Casteele, Sashidhar Varma Sagi, Monika Fischer, Shannon Chang, Matthew Bohm, Dana Lukin, Keith Sultan, Arun Swaminath, David Hudesman, Nitin Gupta, Sunanda Kane, Edward V Loftus, William J Sandborn, Corey A Siegel, Bruce E Sands, Jean-Frederic Colombel, Bo Shen, Parambir S Dulai
Background: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods: Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used to determine rates of LOR to VDZ . Independent predictors of LOR were identified using univariate and multivariable Cox proportional hazard regression...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29774158/efficacy-of-vedolizumab-for-induction-of-clinical-response-and-remission-in-patients-with-moderate-to-severe-inflammatory-bowel-disease-who-failed-at-least-two-tnf-antagonists
#6
Martine De Vos, Barbara Dhooghe, Severine Vermeire, Edouard Louis, Fazia Mana, Ann Elewaut, Peter Bossuyt, Filip Baert, Catherine Reenaers, Marc Van Gossum, Elisabeth Macken, Marc Ferrante, Pieter Hindryckx, Olivier Dewit, Tom Holvoet, Denis Franchimont
Background: Vedolizumab is a recently available monoclonal antibody targeting α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). Objective: The objective of this article is to evaluate the efficacy of vedolizumab induction therapy in anti-TNF-refractory/intolerant UC and CD patients in real life. Methods: A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015)...
April 2018: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/29774052/therapeutic-drug-monitoring-of-vedolizumab-in-inflammatory-bowel-disease-current-data-and-future-directions
#7
REVIEW
Mark G Ward, Miles P Sparrow, Xavier Roblin
The introduction of vedolizumab, a lymphocyte adhesion inhibitor, has expanded the relatively limited therapeutic armamentarium available for Crohn's disease and ulcerative colitis. Despite its effectiveness, both primary nonresponse and secondary loss of response to vedolizumab do occur, as is observed with the use of anti-tumour necrosis factor (TNF) therapy. Further, in a proportion, onset of efficacy may be relatively slow. A large body of data support an exposure-response relationship with anti-TNF drug levels, which has led to therapeutic drug monitoring becoming incorporated into everyday clinical management...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29766731/-current-and-prospective-biologics-and-small-molecules-in-the-treatment-of-inflammatory-bowel-diseases
#8
Milan Buc
Crohns disease (CD) and ulcerative colitis (UC) belong to chronic inflammatory bowel diseases, which are induced by autoimmune processes. While CD is characterized by over-activity of Th1, ILC1, and MAIT cells, UC is mediated by exaggerated activities of Th2 and ILC2 cells and cytokines they produce. Knowledge of the pathogenesis enabled a rational therapy based mostly on biologics and small molecules. TNF is the principal proinflammatory cytokine in both diseases. Anti-TNF monoclonal antibodies, mostly infliximab or adalimumab were therefore introduced to their treatment...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29751166/safety-and-efficacy-of-combination-treatment-with-calcineurin-inhibitors-and-vedolizumab-in-patients-with-refractory-inflammatory-bowel-disease
#9
Britt Christensen, Peter Gibson, Dejan Micic, Ruben J Colman, Sarah R Goeppinger, Olufemmi Kassim, Andres Yarur, Christopher R Weber, Russell D Cohen, David T Rubin
BACKGROUND & AIMS: Little is known about the efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab for patients with Crohn's disease (CD) or ulcerative colitis (UC). We analyzed the outcomes of patients receiving vedolizumab along with calcineurin inhibitors METHODS: We collected data on patients with CD (n=9) or UC (n=11) who began treatment with vedolizumab from May 20, 2014 through March 30, 2015 and received calcineurin inhibitors (tacrolimus or cyclosporin) during the first 12 months of vedolizumab therapy...
May 8, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29740202/anti-integrin-therapy-for-inflammatory-bowel-disease
#10
REVIEW
Sung Chul Park, Yoon Tae Jeen
In inflammatory bowel disease (IBD), tumor necrosis factor plays an important role in mediating inflammation, but several other pathways are also involved in eliciting an inflammatory response. One such pathway is the invasion of the intestinal mucosa by leukocytes. Leukocytes within the systemic circulation move to sites of inflammation, and blocking this pathway could be an important treatment strategy for IBD. Anti-integrin therapy blocks the action of integrin on the surface of circulating immune cells and endothelial cell adhesion molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29730603/vedolizumab-is-associated-with-changes-in-innate-rather-than-adaptive-immunity-in-patients-with-inflammatory-bowel-disease
#11
Sebastian Zeissig, Elisa Rosati, C Marie Dowds, Konrad Aden, Johannes Bethge, Berenice Schulte, Wei Hung Pan, Neha Mishra, Maaz Zuhayra, Marlies Marx, Maren Paulsen, Anne Strigli, Claudio Conrad, Dörthe Schuldt, Anupam Sinha, Henriette Ebsen, Sabin-Christin Kornell, Susanna Nikolaus, Alexander Arlt, Dieter Kabelitz, Mark Ellrichmann, Ulf Lützen, Philip C Rosenstiel, Andre Franke, Stefan Schreiber
OBJECTIVE: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn's disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control...
May 5, 2018: Gut
https://www.readbyqxmd.com/read/29727386/entyvio-lengthen-dose-interval-study-lengthening-vedolizumab-dose-interval-and-the-risk-of-clinical-relapse-in-inflammatory-bowel-disease
#12
Webber Chan, Nicole Lynch, Peter Bampton, Jeff Chang, Alvin Chung, Timothy Florin, David J Hetzel, Simon Jakobovits, Gregory Moore, Paul Pavli, Graham Radford-Smith, Lena Thin, Brandon Baraty, Craig Haifer, Yunki Yau, Rupert W L Leong
BACKGROUND: Vedolizumab (VDZ), an α4β7 anti-integrin antibody, is efficacious in the induction and maintenance of remission in ulcerative colitis (UC) and Crohn's disease (CD). In the GEMINI long-term safety study, enrolled patients received 4-weekly VDZ. Upon completion, patients were switched to 8-weekly VDZ in Australia. The clinical success rate of treatment de-escalation for patients in remission on VDZ has not been described previously. AIM: To determine the proportion of patients who relapsed after switching from 4 to 8-weekly VDZ, the mean time to relapse, and the recapture rate when switching back to 8-weekly dosing...
April 30, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29718223/outcomes-of-treatment-for-latent-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-biologic-therapy
#13
Guilherme P Ramos, Gregory Stroh, Badr Al-Bawardy, William A Faubion, Konstantinos A Papadakis, Patricio Escalante
Background: Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effectiveness of LTBI treatment in IBD patients receiving biologic therapy. Methods: There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016...
April 26, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29704680/evidence-to-support-monitoring-of-vedolizumab-trough-concentrations-in-patients-with-inflammatory-bowel-diseases
#14
Erwin Dreesen, Bram Verstockt, Sumin Bian, Magali de Bruyn, Griet Compernolle, Sophie Tops, Maja Noman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
BACKGROUND & AIMS: Trough concentrations of vedolizumab were found to correlate with clinical response in phase 3 studies of patients with ulcerative colitis (UC) or Crohn's disease (CD). Nevertheless, there are no solid data to support monitoring of vedolizumab trough concentrations in treated patients. We investigated the correlation between vedolizumab exposure and response in a real-world population and aimed to identify patient factors that affect exposure and response. METHODS: We performed a retrospective cohort study of 179 consecutive patients (66 with UC and 113 with CD) who began vedolizumab therapy from September 1, 2015 through October 1, 2016 at University Hospitals Leuven, Belgium...
April 25, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29673053/vedolizumab-as-a-rescue-therapy-for-patients-with-medically-refractory-crohn-s-disease
#15
Kristen T Crowell, Andrew Tinsley, Emmanuelle D Williams, Matthew D Coates, Anne Bobb, Walter A Koltun, Evangelos Messaris
AIM: Vedolizumab, a monoclonal antibody resulting in gut-selective anti-inflammatory activity, was FDA-approved in 2014 for use in patients with Crohn's disease (CD). The aim of the study was to investigate the efficacy of vedolizumab as a rescue therapy when other medical therapies have failed. METHOD: A retrospective review was performed on consecutive CD patients receiving vedolizumab between May 2014 and March 2016 at the Penn State Hershey IBD Center. These patients were unresponsive or intolerant to TNF antagonist therapy, and previously would have been surgical candidates...
April 19, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
https://www.readbyqxmd.com/read/29668995/predictive-models-of-therapeutic-response-to-vedolizumab-a-novel-step-into-personalized-medicine-in-crohn-s-disease
#16
P Veyrard, G Boschetti, S Nancey, X Roblin
No abstract text is available yet for this article.
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668955/what-is-the-risk-of-progressive-multifocal-leukoencephalopathy-in-patients-with-ulcerative-colitis-or-crohn-s-disease-treated-with-vedolizumab
#17
Timothy Card, Jing Xu, Huifang Liang, Fatima Bhayat
Background: Progressive multifocal leukoencephalopathy is a serious condition linked to certain diseases and immunosuppressant therapies, including the α4 integrin antagonist natalizumab. No cases have been reported to date with vedolizumab, a selective antagonist of the α4β7 integrin expressed on gut-homing lymphocytes. This analysis aimed to describe the current and future expected occurrence of progressive multifocal leukoencephalopathy with vedolizumab use, were the risk the same as in other populations in which this disease has been studied...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668917/nonadherence-to-biologic-therapies-in-inflammatory-bowel-disease
#18
Brian J Wentworth, Ross C D Buerlein, Anne G Tuskey, M Ashley Overby, Mark E Smolkin, Brian W Behm
Background: Nonadherence to medications is common with patients with inflammatory bowel disease (IBD). The aim of this study was to assess adherence to biologic medications prescribed for IBD and to identify risk factors for biologic nonadherence. Methods: This was a single center retrospective cohort study investigating IBD patient adherence to biologic therapies over a 2-year period from September 2014 to September 2016. Specialty pharmacy and infusion center records were obtained and a modified medication possession ratio was calculated...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668916/extraintestinal-manifestations-in-vedolizumab-and-anti-tnf-treated-patients-with-inflammatory-bowel-disease
#19
Marla C Dubinsky, Raymond K Cross, William J Sandborn, Millie Long, Xue Song, Nianwen Shi, Yao Ding, Samantha Eichner, Brandee Pappalardo, Arijit Ganguli, Anthony Wang
Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti-tumor necrosis factor (anti-TNF) therapies. Methods: Adult IBD patients receiving VDZ or anti-TNFs were identified from the MarketScan claims database from September 28, 2012, through September 30, 2016...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668915/predicting-corticosteroid-free-biologic-remission-with-vedolizumab-in-crohn-s-disease
#20
Akbar K Waljee, Boang Liu, Kay Sauder, Ji Zhu, Shail M Govani, Ryan W Stidham, Peter D R Higgins
Background and Aims: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort...
April 13, 2018: Inflammatory Bowel Diseases
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"